Optimizing Anticoagulation in Valvular Heart Disease: Navigating NOACs and VKAs

Area of Science:

• Cardiology
• Pharmacology
• Internal Medicine

Background:

• Non-vitamin K antagonist oral anticoagulants (NOACs) offer advantages over vitamin K antagonists (VKAs) for nonvalvular atrial fibrillation (AF).
• NOACs possess favorable pharmacological properties like rapid onset/offset and fixed dosing, reducing monitoring needs.
• Investigating NOACs in patients with AF and valvular heart disease (VHD) is a growing area of research.

Purpose of the Study:

• To review and identify specific clinical scenarios for prescribing NOACs in patients with VHD.
• To focus on the application of NOACs across different types of valvulopathy.

Main Methods:

• Analysis of existing clinical trials excluding specific VHD patient groups (mechanical valves, moderate/severe mitral stenosis).
• Review of ongoing randomized controlled trials (RCTs) investigating NOACs in moderate to severe rheumatic mitral stenosis.
• Evaluation of recent trial data concerning NOAC use in patients with AF and bioprosthetic or transcatheter heart valves.

Main Results:

• Previous trials demonstrated NOAC benefits over VKAs in certain VHD populations, excluding mechanical valves and severe mitral stenosis.
• Recent studies indicate NOAC safety in patients with AF and bioprosthetic or transcatheter heart valves.
• Ongoing RCTs aim to provide definitive evidence for NOACs in moderate to severe rheumatic mitral stenosis.

Conclusions:

• Further research is required to establish NOAC efficacy and safety in patients with mechanical prosthetic valves.
• Defining precise indications for NOACs in various VHD types, including mitral stenosis and mechanical valves, is crucial.
• Current evidence supports NOAC use in specific VHD subgroups, with ongoing studies expanding this understanding.